Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273893 · ClinicalTrials.gov registry record · NA
Lymphocyte Depletion and Change in Lymphocyte Functionality
A NA study of Lymphocyte Depletion, sponsored by University of Virginia.
- Active
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT04273893: Active NA study of Lymphocyte Depletion, sponsored by University of Virginia.
NCT04273893 is a NA study of Lymphocyte Depletion that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04273893, a NA study of Lymphocyte Depletion, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Lymphocytes are a type of white blood cell (WBC) responsible for adaptive immunity. Thoracic tumors are adjacent to many blood/immune rich organs including the great vessels, heart, thoracic-spine, and lymph-node-stations. During radiation treatment the impact to lymphocytes can be significant. This may cause a decrease in the amount of lymphocytes. A researcher at UVA has created a system to predict and reduce the immune cell reduction following lung SBRT treatments beyond standard of care. The predicted decrease in lymphocytes will be compared to the actual decrease in lymphocytes found in peripheral blood. Researchers have found a way to give radiation that they think will result in a smaller decrease in lymphocytes after radiation. There will be two groups in this study, about half of the participants will have their radiation designed to decrease radiation to organs with a lot of blood and the other half will receive standard radiation therapy. Participants are being asked to take part in this study because the participants have been diagnosed with NSCLC and will be receiving a type of radiation therapy called stereotactic body radiation therapy (SBRT) where high doses of radiation will be delivered to the tumor, while minimizing damage to healthy surrounding tissues.
Primary Outcome
Mean percentage difference of measured absolute lymphocyte counts between the baseline and at each time points for the two separate arms
Conditions Studied
Interventions
- RADIATION SBRT with additional treatment planning dose optimization
- RADIATION SBRT with standard of care planning only
- DIAGNOSTIC_TEST Blood Draws
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2025-06-01 |
| Phase | NA |
What the registry record for NCT04273893 still lists
NCT04273893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Lymphocyte Depletion appearing as the primary indexed condition, and to 3 interventions - of which SBRT with additional treatment planning dose optimization is the first listed.
NCT04273893 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04273893 about?
NCT04273893 is a clinical study titled "Lymphocyte Depletion and Change in Lymphocyte Functionality". Lymphocytes are a type of white blood cell (WBC) responsible for adaptive immunity. Thoracic tumors are adjacent to many blood/immune rich organs including the great vessels, heart, thoracic-spine, and lymph-node-stations. During radiation treatment the impact to lymphocytes can be significant. This...
What is the current status of trial NCT04273893?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2020-02-12. Estimated completion is 2025-06-01.
What conditions does trial NCT04273893 study?
This clinical trial studies the following conditions: Lymphocyte Depletion.
What interventions are being tested in trial NCT04273893?
The interventions under investigation include: SBRT with additional treatment planning dose optimization (RADIATION), SBRT with standard of care planning only (RADIATION), Blood Draws (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04273893?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04273893 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04273893's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI